ES2777228T3 - Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer - Google Patents
Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer Download PDFInfo
- Publication number
- ES2777228T3 ES2777228T3 ES14779403T ES14779403T ES2777228T3 ES 2777228 T3 ES2777228 T3 ES 2777228T3 ES 14779403 T ES14779403 T ES 14779403T ES 14779403 T ES14779403 T ES 14779403T ES 2777228 T3 ES2777228 T3 ES 2777228T3
- Authority
- ES
- Spain
- Prior art keywords
- regions
- indicator
- loh
- patient
- tai
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 477
- 201000011510 cancer Diseases 0.000 title claims abstract description 453
- 238000000034 method Methods 0.000 title claims abstract description 265
- 230000004044 response Effects 0.000 title claims abstract description 50
- 230000007812 deficiency Effects 0.000 title claims description 99
- 238000011282 treatment Methods 0.000 title claims description 60
- 230000006801 homologous recombination Effects 0.000 title description 10
- 238000002744 homologous recombination Methods 0.000 title description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 298
- 238000011269 treatment regimen Methods 0.000 claims abstract description 106
- 210000003917 human chromosome Anatomy 0.000 claims abstract description 90
- 210000000349 chromosome Anatomy 0.000 claims abstract description 71
- 239000012661 PARP inhibitor Substances 0.000 claims abstract description 67
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims abstract description 67
- 229940045799 anthracyclines and related substance Drugs 0.000 claims abstract description 62
- 239000012623 DNA damaging agent Substances 0.000 claims abstract description 61
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims abstract description 58
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims abstract description 58
- -1 anthracycline Substances 0.000 claims abstract description 42
- 230000000392 somatic effect Effects 0.000 claims abstract description 22
- 230000007704 transition Effects 0.000 claims abstract description 13
- 210000002230 centromere Anatomy 0.000 claims abstract description 12
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 102000036365 BRCA1 Human genes 0.000 claims description 126
- 101150072950 BRCA1 gene Proteins 0.000 claims description 118
- 108700020463 BRCA1 Proteins 0.000 claims description 110
- 238000012360 testing method Methods 0.000 claims description 62
- 208000026310 Breast neoplasm Diseases 0.000 claims description 57
- 206010006187 Breast cancer Diseases 0.000 claims description 56
- 230000002950 deficient Effects 0.000 claims description 49
- 230000035772 mutation Effects 0.000 claims description 46
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 34
- 101150008921 Brca2 gene Proteins 0.000 claims description 31
- 229960004316 cisplatin Drugs 0.000 claims description 26
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 102000052609 BRCA2 Human genes 0.000 claims description 23
- 108700020462 BRCA2 Proteins 0.000 claims description 23
- 229940079593 drug Drugs 0.000 claims description 20
- 206010033128 Ovarian cancer Diseases 0.000 claims description 18
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 18
- 229960004679 doxorubicin Drugs 0.000 claims description 17
- 229960004768 irinotecan Drugs 0.000 claims description 17
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 17
- 229960000303 topotecan Drugs 0.000 claims description 17
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 17
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 15
- 210000000481 breast Anatomy 0.000 claims description 15
- 201000004101 esophageal cancer Diseases 0.000 claims description 15
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 15
- 229960000572 olaparib Drugs 0.000 claims description 15
- 229960004562 carboplatin Drugs 0.000 claims description 14
- 190000008236 carboplatin Chemical compound 0.000 claims description 14
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 14
- 229950005566 picoplatin Drugs 0.000 claims description 14
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 13
- 230000002611 ovarian Effects 0.000 claims description 11
- 230000002939 deleterious effect Effects 0.000 claims description 9
- 210000003765 sex chromosome Anatomy 0.000 claims description 9
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 284
- 108020004414 DNA Proteins 0.000 description 88
- 238000004458 analytical method Methods 0.000 description 39
- 238000003556 assay Methods 0.000 description 37
- 239000003795 chemical substances by application Substances 0.000 description 34
- 238000004590 computer program Methods 0.000 description 34
- 230000015654 memory Effects 0.000 description 34
- 238000012163 sequencing technique Methods 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 33
- 108700028369 Alleles Proteins 0.000 description 32
- 239000013610 patient sample Substances 0.000 description 31
- 230000005855 radiation Effects 0.000 description 31
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 26
- 210000004602 germ cell Anatomy 0.000 description 25
- 230000037361 pathway Effects 0.000 description 21
- 238000004891 communication Methods 0.000 description 19
- 108700040618 BRCA1 Genes Proteins 0.000 description 16
- 108700010154 BRCA2 Genes Proteins 0.000 description 16
- 238000007477 logistic regression Methods 0.000 description 16
- 230000011987 methylation Effects 0.000 description 15
- 238000007069 methylation reaction Methods 0.000 description 15
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical group NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 229950002133 iniparib Drugs 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 229910052697 platinum Inorganic materials 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 12
- 230000002759 chromosomal effect Effects 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000004393 prognosis Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 12
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 11
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000011109 contamination Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229940044683 chemotherapy drug Drugs 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 238000011518 platinum-based chemotherapy Methods 0.000 description 9
- 210000001082 somatic cell Anatomy 0.000 description 9
- 208000031404 Chromosome Aberrations Diseases 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 231100000005 chromosome aberration Toxicity 0.000 description 8
- 231100000518 lethal Toxicity 0.000 description 8
- 230000001665 lethal effect Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 230000007547 defect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 238000009007 Diagnostic Kit Methods 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010064571 Gene mutation Diseases 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 4
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 229940123237 Taxane Drugs 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000002256 antimetabolite Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 231100000225 lethality Toxicity 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 230000008775 paternal effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102000003915 DNA Topoisomerases Human genes 0.000 description 3
- 108090000323 DNA Topoisomerases Proteins 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- 229940028652 abraxane Drugs 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
- 229960001433 erlotinib Drugs 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229960002584 gefitinib Drugs 0.000 description 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229960004891 lapatinib Drugs 0.000 description 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 238000000491 multivariate analysis Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 229960001972 panitumumab Drugs 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 229960001796 sunitinib Drugs 0.000 description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 description 2
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 2
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 2
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000010572 basal-like breast carcinoma Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000013388 immunohistochemistry analysis Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 2
- 238000010202 multivariate logistic regression analysis Methods 0.000 description 2
- 238000009099 neoadjuvant therapy Methods 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 239000012827 ATM inhibitor Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 1
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 description 1
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 description 1
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 1
- 108010066370 Keratin-20 Proteins 0.000 description 1
- 108010070507 Keratin-7 Proteins 0.000 description 1
- 229910015837 MSH2 Inorganic materials 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000001195 RAD51 Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013442 quality metrics Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- 229950011257 veliparib Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 238000012049 whole transcriptome sequencing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809105P | 2013-04-05 | 2013-04-05 | |
| US201361913762P | 2013-12-09 | 2013-12-09 | |
| PCT/US2014/033014 WO2014165785A2 (en) | 2013-04-05 | 2014-04-04 | Methods and materials for assessing homologous recombination deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2777228T3 true ES2777228T3 (es) | 2020-08-04 |
Family
ID=51659359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14779403T Active ES2777228T3 (es) | 2013-04-05 | 2014-04-04 | Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20140363521A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3693475A1 (cg-RX-API-DMAC10.html) |
| JP (5) | JP6625045B2 (cg-RX-API-DMAC10.html) |
| AU (3) | AU2014248007B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2908745C (cg-RX-API-DMAC10.html) |
| DK (1) | DK2981624T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2777228T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT2981624T (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014165785A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| EP3225697A3 (en) | 2010-12-30 | 2017-11-22 | Foundation Medicine, Inc. | Optimization of multigene analysis of tumor samples |
| ES2768344T3 (es) | 2011-06-17 | 2020-06-22 | Myriad Genetics Inc | Métodos y materiales para evaluar el desequilibrio alélico |
| JP6325453B2 (ja) | 2011-12-21 | 2018-05-16 | ミリアド・ジェネティックス・インコーポレイテッド | ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| ES2687024T3 (es) | 2012-02-23 | 2018-10-23 | Children's Medical Center Corporation | Procedimientos para predecir la respuesta contra el cáncer |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| CA2931181C (en) | 2013-12-09 | 2023-01-24 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US10545151B2 (en) | 2014-02-21 | 2020-01-28 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| DK3686288T3 (da) | 2014-08-15 | 2023-05-22 | Myriad Genetics Inc | Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens |
| ES2989276T3 (es) * | 2014-12-05 | 2024-11-25 | Found Medicine Inc | Análisis multigénico de muestras tumorales |
| US20160160294A1 (en) * | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| US20180148792A1 (en) | 2015-05-19 | 2018-05-31 | T.S. Sridhar | Method for Identification of a Deficient BRCA1 Function |
| CN115341033A (zh) * | 2015-11-03 | 2022-11-15 | 艾匹克科学公司 | 一种表征疾病异质性的方法 |
| WO2017106365A1 (en) * | 2015-12-14 | 2017-06-22 | Myriad Genetics, Inc. | Methods for measuring mutation load |
| US20190025312A1 (en) * | 2016-01-06 | 2019-01-24 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
| WO2017165270A1 (en) * | 2016-03-21 | 2017-09-28 | Myriad Genetics, Inc. | Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer |
| WO2017178509A1 (en) | 2016-04-12 | 2017-10-19 | Xentech | Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| WO2017191074A1 (en) * | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| US12062416B2 (en) | 2016-05-01 | 2024-08-13 | Genome Research Limited | Method of characterizing a DNA sample |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| KR20210035167A (ko) | 2018-06-11 | 2021-03-31 | 파운데이션 메디신 인코포레이티드 | 게놈 변경을 평가하기 위한 조성물 및 방법 |
| JPWO2020137076A1 (ja) * | 2018-12-28 | 2021-11-11 | 国立大学法人 東京大学 | Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法 |
| US10975445B2 (en) | 2019-02-12 | 2021-04-13 | Tempus Labs, Inc. | Integrated machine-learning framework to estimate homologous recombination deficiency |
| WO2021119311A1 (en) | 2019-12-10 | 2021-06-17 | Tempus Labs, Inc. | Systems and methods for predicting homologous recombination deficiency status of a specimen |
| CN114829624A (zh) * | 2019-12-16 | 2022-07-29 | 安捷伦科技有限公司 | 基因组瘢痕测定和相关方法 |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN111883211B (zh) * | 2020-08-07 | 2021-04-23 | 张哲� | 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法 |
| CN111676277B (zh) * | 2020-08-12 | 2020-12-15 | 臻和(北京)生物科技有限公司 | 一种基于二代测序技术测定基因组不稳定的方法及试剂盒 |
| CN112164420B (zh) | 2020-09-07 | 2021-07-20 | 厦门艾德生物医药科技股份有限公司 | 一种基因组瘢痕模型的建立方法 |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| JP7585015B2 (ja) | 2020-12-04 | 2024-11-18 | 株式会社東芝 | 核酸構築物のセット、キット、検出方法及び薬剤効果予測方法 |
| US20240052423A1 (en) * | 2020-12-07 | 2024-02-15 | Pfizer Inc. | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
| CN114096681B (zh) * | 2021-01-10 | 2024-06-21 | 行动基因(智财)有限公司 | 同源重组缺失检测方法及其试剂组 |
| BE1029144B1 (fr) | 2021-02-25 | 2022-09-20 | Oncodna | Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé |
| CN112820351A (zh) * | 2021-03-01 | 2021-05-18 | 江苏医联生物科技有限公司 | 检测肿瘤患者的突变和hrd评分指导用药的方法 |
| AU2022299105A1 (en) * | 2021-06-25 | 2024-01-04 | Foundation Medicine, Inc. | System and method of classifying homologous repair deficiency |
| CA3240150A1 (en) * | 2021-12-08 | 2023-06-15 | Alexander Gutin | Methods and materials for assessing homologous recombination deficiency in breast cancer subtypes |
| KR102523938B1 (ko) * | 2022-02-04 | 2023-04-19 | 가톨릭대학교 산학협력단 | 상동 재조합 결핍증 예측 모델의 모델링 방법 |
| US20260139317A1 (en) | 2022-10-19 | 2026-05-21 | Vib Vzw | Method of Determining Loss of Heterozygosity Status of a Tumor |
| EP4792336A1 (en) | 2023-10-10 | 2026-08-19 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| EP4791901A1 (en) | 2023-10-10 | 2026-08-19 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| ZA928771B (en) | 1991-11-15 | 1993-09-08 | Smithkline Beecham Corp | Combination chemotherapy |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| US6887996B2 (en) | 2000-12-01 | 2005-05-03 | Guilford Pharmaceuticals Inc. | Compounds and their use |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| WO2005002508A2 (en) | 2003-06-11 | 2005-01-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| WO2005004805A2 (en) | 2003-07-02 | 2005-01-20 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| MXPA06000993A (es) | 2003-07-25 | 2006-08-31 | Cancer Rec Tech Ltd | Inhbidores triciclicos de parp. |
| CA2535762A1 (en) | 2003-08-13 | 2005-03-17 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
| DE602006018299D1 (de) | 2005-06-30 | 2010-12-30 | Bionumerik Pharmaceuticals Inc | Platinanaloga mit monoazolligand |
| KR100925337B1 (ko) * | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| EP3327148B1 (en) | 2010-06-18 | 2021-03-17 | Myriad Genetics, Inc. | Methods of predicting the status of brca1 and brca2 genes in a cancer cell |
| ES2704303T3 (es) * | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| ES2687024T3 (es) * | 2012-02-23 | 2018-10-23 | Children's Medical Center Corporation | Procedimientos para predecir la respuesta contra el cáncer |
| DK2981624T3 (da) * | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
-
2014
- 2014-04-04 DK DK14779403.6T patent/DK2981624T3/da active
- 2014-04-04 EP EP19216740.1A patent/EP3693475A1/en active Pending
- 2014-04-04 ES ES14779403T patent/ES2777228T3/es active Active
- 2014-04-04 US US14/245,576 patent/US20140363521A1/en not_active Abandoned
- 2014-04-04 AU AU2014248007A patent/AU2014248007B2/en active Active
- 2014-04-04 CA CA2908745A patent/CA2908745C/en active Active
- 2014-04-04 JP JP2016506657A patent/JP6625045B2/ja active Active
- 2014-04-04 PT PT147794036T patent/PT2981624T/pt unknown
- 2014-04-04 EP EP14779403.6A patent/EP2981624B1/en active Active
- 2014-04-04 WO PCT/US2014/033014 patent/WO2014165785A2/en not_active Ceased
-
2017
- 2017-07-17 US US15/651,652 patent/US20180030544A1/en not_active Abandoned
-
2019
- 2019-04-26 JP JP2019085187A patent/JP7522539B2/ja active Active
-
2020
- 2020-06-17 AU AU2020204028A patent/AU2020204028B2/en active Active
- 2020-11-25 JP JP2020194936A patent/JP7522643B2/ja active Active
-
2021
- 2021-06-21 US US17/353,279 patent/US20210310079A1/en active Pending
-
2022
- 2022-08-04 AU AU2022211880A patent/AU2022211880B2/en active Active
- 2022-10-21 JP JP2022169085A patent/JP7641938B2/ja active Active
-
2025
- 2025-02-25 JP JP2025027653A patent/JP2025090619A/ja active Pending
- 2025-03-24 US US19/088,496 patent/US20250223655A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016523511A (ja) | 2016-08-12 |
| JP2021036903A (ja) | 2021-03-11 |
| EP3693475A1 (en) | 2020-08-12 |
| AU2020204028B2 (en) | 2022-08-18 |
| JP2025090619A (ja) | 2025-06-17 |
| AU2014248007A1 (en) | 2015-10-15 |
| US20180030544A1 (en) | 2018-02-01 |
| AU2014248007B2 (en) | 2020-03-26 |
| JP7641938B2 (ja) | 2025-03-07 |
| US20210310079A1 (en) | 2021-10-07 |
| US20140363521A1 (en) | 2014-12-11 |
| DK2981624T3 (da) | 2020-03-02 |
| EP2981624B1 (en) | 2019-12-18 |
| PT2981624T (pt) | 2020-03-23 |
| JP7522643B2 (ja) | 2024-07-25 |
| CA2908745A1 (en) | 2014-10-09 |
| JP2023012488A (ja) | 2023-01-25 |
| WO2014165785A2 (en) | 2014-10-09 |
| NZ712663A (en) | 2021-07-30 |
| EP2981624A4 (en) | 2016-11-30 |
| CA2908745C (en) | 2023-03-14 |
| EP2981624A2 (en) | 2016-02-10 |
| AU2022211880B2 (en) | 2025-05-29 |
| JP7522539B2 (ja) | 2024-07-25 |
| AU2022211880A1 (en) | 2022-09-01 |
| JP6625045B2 (ja) | 2019-12-25 |
| AU2020204028A1 (en) | 2020-07-09 |
| US20250223655A1 (en) | 2025-07-10 |
| JP2019165731A (ja) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2800673T3 (es) | Métodos y materiales para evaluar una deficiencia de recombinación homóloga | |
| JP7641938B2 (ja) | 相同組換え欠損を評価するための方法および材料 | |
| ES2862331T3 (es) | Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer | |
| ES2759533T5 (es) | Métodos y materiales para evaluar la pérdida de heterocigosidad | |
| TWI861616B (zh) | 用於評估乳癌亞型中同源重組缺陷之方法及材料 | |
| HK40098329A (en) | Methods and materials for assessing homologous recombination deficiency | |
| HK40098329B (en) | Methods and materials for assessing homologous recombination deficiency | |
| NZ712663B2 (en) | Methods and materials for assessing homologous recombination deficiency |